CO54 Recurrence-Free Survival (RFS) as a Surrogate Endpoint (SE) for Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis of Randomized Controlled Trials (RCTs)

Use of valid SEs enables assessment of long-term efficacy of treatments in absence of OS from the RCTs. We evaluated RFS as an SE for OS in resected stage II/III melanoma using trial-level data.

Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: L. Leung, J. Kirkwood, S. Srinivasan, M. Dyer, A. Qian, M.M. Pourrahmat, E. Kasireddy, J.R. May, A. Moshyk, M. Kurt Source Type: research